Brief Report: Acamprosate in Fragile X Syndrome

Diagnostic and Statistical Manual of Mental Disorders

Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,842 · see citing works

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069 · see citing works

Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065 · see citing works

Untitled work

(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works

The mGluR theory of fragile X mental retardation

Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · see citing works

Absence of expression of the FMR-1 gene in fragile X syndrome

Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476 · see citing works

Correction of Fragile X Syndrome in Mice

Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979 · see citing works

The FMR–1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation

Devys, D., Lutz, Y., Rouyer, N., Bellocq, J., & Mandel, J. (1993) · Nature Genetics · doi:10.1038/ng0893-335 · Cited by 781 · see citing works

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521 · see citing works

Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome

McBride, S. M. J., Choi, C. H., Wang, Y., Liebelt, D. A., Braunstein, E. M., Ferreiro, D., Sehgal, A., Siwicki, K. K., Dockendorff, T. C., Nguyen, H. T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.038 · Cited by 473 · see citing works

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · see citing works

The fragile X prevalence paradox

Hagerman, P. J. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.059055 · Cited by 343 · see citing works

Synaptic regulation of protein synthesis and the fragile X protein

Greenough, W. T., Klintsova, A. Y., Irwin, S. A., Galvez, R., Bates, K. E., & Weiler, I. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141145998 · Cited by 317 · see citing works

Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice

de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313 · see citing works

Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome

Dölen, G., & Bear, M. F. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.150722 · Cited by 278 · see citing works

Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome

Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215 · see citing works

Neuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action

De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201 · cited 1× · see citing works

Prolonged Epileptiform Discharges Induced by Altered Group I Metabotropic Glutamate Receptor-Mediated Synaptic Responses in Hippocampal Slices of a Fragile X Mouse Model

Chuang, S.-C., Zhao, W., Bauchwitz, R., Yan, Q., Bianchi, R., & Wong, R. K. S. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1777-05.2005 · Cited by 190 · see citing works

Acamprosate: Recent Findings and Future Research Directions

Mann, K. F., Kiefer, F., Spanagel, R., & Littleton, J. M. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00690.x · Cited by 156 · see citing works

α-Tocopherol Protects Against Oxidative Stress in the Fragile X Knockout Mouse: an Experimental Therapeutic Approach for the Fmr1 Deficiency

de Diego-Otero, Y., Romero-Zerbo, Y., Bekay, R. E., Decara, J., Sanchez, L., Fonseca, F. R.-D., & Arco-Herrera, I. D. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.152 · Cited by 133 · see citing works

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors.

Harris, B. R., Prendergast, M., Gibson, D. A., Rogers, D. T., Blanchard, J. A., Holley, R. C., Fu, M. C., Hart, S. R., Pedigo, N. W., & Littleton, J. M. (2002) · PubMed · doi:10.1097/01.alc.0000042011.99580.98 · Cited by 124 · see citing works

Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: Relationship to acamprosate actions

Blednov, Y. A., & Adron Harris, R. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008584 · Cited by 123 · see citing works

Acamprosate Inhibits the Binding and Neurotoxic Effects of Trans‐ACPD, Suggesting a Novel Site of Action at Metabotropic Glutamate Receptors

Harris, B. R., Prendergast, M., Gibson, D. A., Rogers, D. T., Blanchard, J. A., Holley, R. C., Fu, M. C., Hart, S. R., Pedigo, N. W., & Littleton, J. M. (2002) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02484.x · Cited by 111 · see citing works

Metabotropic Glutamate Receptors and Fragile X Mental Retardation Protein: Partners in Translational Regulation at the Synapse

Ronesi, J. A., & Huber, K. M. (2008) · Science Signaling · doi:10.1126/stke.15pe6 · Cited by 106 · see citing works

Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from fragile X mental retardation 1-deficient mice, a pathological model for fragile X syndrome

El Bekay, R., Romero‐Zerbo, Y., Decara, J., Sanchez‐Salido, L., Del Arco‐Herrera, I., Rodríguez‐de Fonseca, F., & De Diego‐Otero, Y. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05939.x · Cited by 85 · see citing works

Acute Effects of Acamprosate and MPEP on Ethanol Drinking‐in‐the‐Dark in Male C57BL/6J Mice

Gupta, T., Syed, Y. M., Revis, A. A., Miller, S. A., Martinez, M., Cohn, K. A., Demeyer, M. R., Patel, K. Y., Brzezinska, W. J., & Rhodes, J. S. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00787.x · Cited by 76 · see citing works

Acamprosate Is Neuroprotective Against Glutamate-Induced Excitotoxicity When Enhanced by Ethanol Withdrawal in Neocortical Cultures of Fetal Rat Brain

AlQatari, M., Khan, S., Harris, B. R., & Littleton, J. M. (2001) · Alcoholism Clinical and Experimental Research · doi:10.1097/00000374-200109000-00006 · Cited by 63 · see citing works

mGlu5 receptor antagonists and their therapeutic potential

Jaeschke, G., Wettstein, J. G., Nordquist, R. E., & Spooren, W. P. J. M. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.2.123 · Cited by 61 · see citing works

Open-Label Memantine in Fragile X Syndrome

Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-009-0807-3 · Cited by 61 · see citing works

Acamprosate Is Neuroprotective Against Glutamate‐Induced Excitotoxicity When Enhanced by Ethanol Withdrawal in Neocortical Cultures of Fetal Rat Brain

al Qatari, M., Khan, S., Harris, B. R., et al. (2001) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02348.x · Cited by 45 · see citing works

Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome

Romero‐Zerbo, S., Decara, J. M., Bekay, R. E., Salido, L. S., del Arco, I., de Fonseca, F. R., & de Diego‐Otero, Y. (2009) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2008.00653.x · Cited by 44 · see citing works

Effects of Acamprosate on Neuronal Receptors and Ion Channels Expressed inXenopusOocytes

Reilly, M. T., Lobo, I. A., McCracken, L. M., Borghese, C. M., Gong, D., Horishita, T., & Harris, R. A. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00569.x · Cited by 34 · see citing works

Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics

Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321 · see citing works

Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome

Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259 · see citing works

Translating Glutamate: From Pathophysiology to Treatment

Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168 · see citing works

Treatment of alcohol-dependent outpatients with acamprosate: a clinical review.

Mason, B. J. (2001) · PubMed · Cited by 117 · see citing works

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients

Pelc, I., Verbanck, P., Bon, O. L., Gavrilovic, M., Lion, K., & Lehert, P. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.1.73 · Cited by 183 · see citing works

Acamprosate—an Anti-Craving Drug for Alcohol Use Disorder (AUD) Pharmacotherapy: Plasma Metabolomics Signatures are Associated With Alcohol Craving Intensity and Acamprosate Treatment Response

Ho, M., Zhang, C., Zhang, L., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.359

Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder

Ho, M., Zhang, C., Moon, I., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.986238 · Cited by 8 · see citing works

PP135—Pharmacometabolomics for individualized treatment of alcoholism: High serum glutamate level is associated with positive response to acamprosate treatment

Choi, D.-S., Nam, H. W., & Karpyak, V. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.157 · Cited by 1 · see citing works